Ocugen
Business Services · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11 Great Valley Pkwy, Malvern, Pennsylva...Phone Number
(484) 328-4701Website
www.ocugen.comRevenue
<$5 MillionStock Symbol
OCGNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
1
About Ocugen
Ocugen is a clinical-stage biotechnology company focused on discovering, developing, and commercializing innovative therapies for rare and underserved eye diseases. The company specializes in ophthalmology research and is advancing a pipeline that includes gene therapies, biologic treatments, and other therapeutic technologies designed to address retinal and ocular surface disorders. Its research programs aim to develop novel solutions for conditions that currently have limited treatment options, with a particular emphasis on inherited retinal diseases and other vision-related disorders. Through scientific research, clinical development, and strategic collaborations, Ocugen works to bring new therapeutic approaches to patients while contributing to advancements in genetic and regenerative medicine within the ophthalmology field.Explore more
Ocugen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ocugen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Ocugen recently announced quarterly report
Ocugen, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Ocugen launches new products
Check out if Ocugen is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Ocugen
Check if Ocugen has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Ocugen has new funding data
Click to see if Ocugen had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Ocugen
Compare insights from companies similar to Ocugen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ocugen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ocugen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ocugen.
Ocugen financials insights
Gather financial insights about Ocugen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$6M
2017
Series B
$7.5M
2020
Debt
$350K
2021
Stock Offering
$23M
2024
Debt
$30M
Ocugen Tech Stack
A closer look at the technologies used by Ocugen
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Ocugen is conducting the OCU400 phase III trial with 140 patients in a 2:1 ratio, covering more than 30 mutations across pediatric to adult populations, with a mobility test refined in collaboration with the FDA to 0.04 lux sensitivity and the trial powered at 95% for responder rates passing two luminance levels.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Ocugen is conducting a phase II/III trial for its Stargardt program (OCU410ST) covering patients aged 3 and above across early to advanced disease stages and a broader lesion size range than competing programs, and holds a Rare Pediatric Disease Designation for this program.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
Ocugen News & Media
OCGN 8-K Filings - Ocugen Inc SEC 8-K - Stock Titan
Every Ocugen Inc (OCGN) 8-K filed with the SEC in the last 24 months, newest first, each with a summary and the impact and sentiment scores our analysis gives it.Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for GA secondary to dry age-related macular degeneration (dAMD). The Company also highlighted the recent FDA RMAT designation for OCU410, which supportOcugen to Participate in Upcoming September Investor and Industry Conferences
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026.Ocugen (OCGN) Q2 2026 Earnings Call Transcript
Gene therapy developer advances three Phase III programs toward 2028 regulatory filings.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ocugen
Sign Up For FreeTo access detailed company insights
Ocugen is a clinical-stage biotechnology company focused on discovering, developing, and commercializing innovative therapies for rare and underserved eye diseases. The company specializes in ophthalmology research and is advancing a pipeline that includes gene therapies, biologic treatments, and other therapeutic technologies designed to address r... Read More
